Tofacitinib group:Tofacitinib

3 trials

Sponsors

Ruijin Hospital, The Second Hospital of Shanxi Medical University, Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China

Conditions

Vitiligopalindromic rheumatismsystemic sclerosis

Early Phase 1

JAKs inhibitor tofacitinib reduces skin thickness and improves lung function in patients with systemic sclerosis

RecruitingChiCTR2300074515

The Second Hospital of Shanxi Medical Universitysystemic sclerosis

Start: 2022-06-01Updated: 2023-08-21

Efficacy and Safety of Tofacitinib versus Glucocorticoids in Patients with Active Segmental Vitiligo: A 72-Week, Single-Center, Parallel-Control, Open-Label, Randomized Extension Trial

Active, not recruitingChiCTR2500111079

Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, ChinaVitiligo

Start: 2025-10-31Updated: 2025-10-27

Phase 1

A randomized controlled study comparing the efficacy of tofacitinib and hydroxychloroquine in the treatment of new-onset palindromic rheumatism

Active, not recruitingChiCTR2200061060

Ruijin Hospitalpalindromic rheumatism

Start: 2022-06-01Updated: 2023-03-26